Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2022-000845-34 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a PAC study after PCV13 launch in China. Based on recommendation from China Agency, Pfizer was required to conduct a descriptive immunogenicity study to measure the antibody levels at the time of disease onset.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PCV13 group and non PCV13 group | Other | This study plan to recruit those young patients who have or not have got PCV13 vaccine before study start |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PCV13 PAC study | Biological | To test the serotype-specific IgG geometric mean concentration (GMC) and MOPA geometric mean titers (GMT) for each of the pneumococcal serotypes measured at the time of diagnosis of clinical pneumonia. |
| Measure | Description | Time Frame |
|---|---|---|
| Geometric Mean Concentrations (GMCs) of Pneumococcal Immunoglobulin G (IgG) by Cohort | Approximately 5 mL of blood sample was collected within 24 hours of enrollment. Blood must have been drawn from peripheral veins (eg, arm, foot, or scalp veins). Serum concentrations of anticapsular IgG were determined by enzyme-linked immunosorbent assay (ELISA) for each of the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in all participants with a collected blood sample. | Day 1 |
| Geometric Mean Titers (GMTs) of Pneumococcal Multiplex Opsonophagocytic Activity (MOPA) by Cohort | Approximately 5 mL of blood sample was collected within 24 hours of enrollment. Blood must have been drawn from peripheral veins (eg, arm, foot, or scalp veins). Serum levels of MOPA for each of the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in all 13vPnC cohort participants with adequate blood volume. In the Non-13vPnC cohort, a sample of participants with adequate blood volume was selected, to be equal to the number of the 13vPnC Cohort included for MOPA testing. Titer was expressed as reciprocal of the highest serum dilution. | Day 1 |
| GMCs of Pneumococcal IgG by Cohort and Vaccine Type (VT) Carriage Status - Subgroup Analysis | Approximately 5 mL of blood sample was collected within 24 hours of enrollment. Blood must have been drawn from peripheral veins (eg, arm, foot, or scalp veins). Serum concentrations of anticapsular IgG were determined by ELISA for each of the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in all participants with a collected blood sample. For each cohort, participants were assigned to 2 subgroups: Participant in whom a 13vPnC VT strain had been isolated from the respiratory tract, and participant from whom a 13vPnC VT strain had not been isolated from the respiratory tract (VT carrier versus without VT carrier). | Day 1 |
| GMTs of Pneumococcal MOPA by Cohort and VT Carriage Status - Subgroup Analysis |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Infant or child who is a family member of:
Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
Blood draw is counter indicated.
Previous participation in this study within 30 days.
Previous vaccination with licensed or investigational pneumococcal vaccine. This excludes previous vaccination with 13vPnC as per the approved recommendations in China.
Received blood, blood fractions, plasma, or immunoglobulins within 3 months of the study blood draw.
Hospital acquired pneumonia (ie, onset >48 hours after hospitalization).
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Children's Hospital of Soochow University | Suzhou | Jiangsu | 215003 | China |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
Not provided
Not provided
Not provided
Not provided
No vaccines were administered during the study.
Children hospitalized with a diagnosis of clinical pneumonia were considered for the study. Participants participated in the study for 1 day. Participants were followed for 12 hours after blood draw and deep respiratory aspirate if collected as a study procedure. A total of 300 participants were enrolled in this study.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | 13vPnC Cohort | The vaccination history of 13-valent pneumococcal conjugate vaccine (13vPnC) initially was obtained either from the participant's parent/caregiver; confirmation of 13vPnC receipt from vaccine book or image of vaccine book was required. If 13vPnc vaccination was confirmed as received, and all other inclusion/exclusion criteria were met, this participant was enrolled and assigned to the vaccinated group (ie, 13vPnC Cohort). No vaccines were administered during the study. |
| FG001 | Non-13vPnC Cohort | The vaccination history of 13vPnC initially was obtained either from the participant's parent/caregiver; confirmation of 13vPnC receipt from vaccine book or image of vaccine book was required. If 13vPnC vaccination was confirmed as not received, and all other inclusion / exclusion criteria were met, this participant was enrolled and assigned to the unvaccinated group (ie, Non-13vPnC Cohort). No vaccines were administered during the study. |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Analysis population for baseline characteristics included all participants who signed the informed consent document.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | 13vPnC Cohort | The vaccination history of 13-valent pneumococcal conjugate vaccine (13vPnC) initially was obtained either from the participant's parent/caregiver; confirmation of 13vPnC receipt from vaccine book or image of vaccine book was required. If 13vPnc vaccination was confirmed as received, and all other inclusion/exclusion criteria were met, this participant was enrolled and assigned to the vaccinated group (ie, 13vPnC Cohort). No vaccines were administered during the study. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Customized | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Geometric Mean Concentrations (GMCs) of Pneumococcal Immunoglobulin G (IgG) by Cohort | Approximately 5 mL of blood sample was collected within 24 hours of enrollment. Blood must have been drawn from peripheral veins (eg, arm, foot, or scalp veins). Serum concentrations of anticapsular IgG were determined by enzyme-linked immunosorbent assay (ELISA) for each of the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in all participants with a collected blood sample. | Analysis population for this outcome measure (OM) included all participants who signed the informed consent document, met all inclusion/exclusion criteria, and had at least 1 immunogenicity assay value available for analysis. Overall number of participants analyzed indicates the number of participants in this analysis population. Number Analyzed in each row indicates the number of participants with valid and determinate assay results for the specified serotype. | Posted | Geometric Mean | 95% Confidence Interval | microgram per milliliter (µg/mL) | Day 1 |
|
From the time of the blood draw or aspirate collection through and including 12 hours on Day 1
The same event may appear as both an AE and an SAE. However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as non-serious in another participant, or 1 participant may have experienced both a serious and non-serious event during the study. Total number at risk below refers to the number of participants evaluable for SAEs or AEs.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | 13vPnC Cohort | The vaccination history of 13-valent pneumococcal conjugate vaccine (13vPnC) initially was obtained either from the participant's parent/caregiver; confirmation of 13vPnC receipt from vaccine book or image of vaccine book was required. If 13vPnc vaccination was confirmed as received, and all other inclusion/exclusion criteria were met, this participant was enrolled and assigned to the vaccinated group (ie, 13vPnC Cohort). No vaccines were administered during the study. |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Pfizer ClinicalTrials.gov Call Center | Pfizer, Inc | 1-800-718-1021 | ClinicalTrials.gov_Inquiries@pfizer.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Jul 25, 2018 | Dec 1, 2022 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | May 22, 2020 | Dec 1, 2022 | SAP_001.pdf |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Approximately 5 mL of blood sample was collected within 24 hours of enrollment. Blood must have been drawn from peripheral veins (eg, arm, foot, or scalp veins). Serum levels of MOPA for each of the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in all 13vPnC cohort participants with adequate blood volume. In the Non-13vPnC cohort, a sample of participants with adequate blood volume was selected, to be equal to the number of the 13vPnC Cohort included for MOPA testing. For each cohort, participants were assigned to 2 subgroups: Participant in whom a 13vPnC VT strain had been isolated from the respiratory tract, and participant from whom a 13vPnC VT strain had not been isolated from the respiratory tract (VT carrier versus without VT carrier). Titer was expressed as reciprocal of the highest serum dilution.
| Day 1 |
| BG001 | Non-13vPnC Cohort | The vaccination history of 13vPnC initially was obtained either from the participant's parent/caregiver; confirmation of 13vPnC receipt from vaccine book or image of vaccine book was required. If 13vPnC vaccination was confirmed as not received, and all other inclusion / exclusion criteria were met, this participant was enrolled and assigned to the unvaccinated group (ie, Non-13vPnC Cohort). No vaccines were administered during the study. |
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Count of Participants | Participants |
|
| OG000 |
| 13vPnC Cohort |
The vaccination history of 13-valent pneumococcal conjugate vaccine (13vPnC) initially was obtained either from the participant's parent/caregiver; confirmation of 13vPnC receipt from vaccine book or image of vaccine book was required. If 13vPnc vaccination was confirmed as received, and all other inclusion/exclusion criteria were met, this participant was enrolled and assigned to the vaccinated group (ie, 13vPnC Cohort). No vaccines were administered during the study. |
| OG001 | Non-13vPnC Cohort | The vaccination history of 13vPnC initially was obtained either from the participant's parent/caregiver; confirmation of 13vPnC receipt from vaccine book or image of vaccine book was required. If 13vPnC vaccination was confirmed as not received, and all other inclusion / exclusion criteria were met, this participant was enrolled and assigned to the unvaccinated group (ie, Non-13vPnC Cohort). No vaccines were administered during the study. |
|
|
|
| Primary | Geometric Mean Titers (GMTs) of Pneumococcal Multiplex Opsonophagocytic Activity (MOPA) by Cohort | Approximately 5 mL of blood sample was collected within 24 hours of enrollment. Blood must have been drawn from peripheral veins (eg, arm, foot, or scalp veins). Serum levels of MOPA for each of the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in all 13vPnC cohort participants with adequate blood volume. In the Non-13vPnC cohort, a sample of participants with adequate blood volume was selected, to be equal to the number of the 13vPnC Cohort included for MOPA testing. Titer was expressed as reciprocal of the highest serum dilution. | Analysis population for this OM included all participants who signed the informed consent document, met all inclusion/exclusion criteria, and had at least 1 immunogenicity assay value available for analysis. Overall number of participants analyzed indicates the number of participants in this analysis population. Number Analyzed in each row indicates the number of participants with valid and determinate assay results for the specified serotype. | Posted | Number | 95% Confidence Interval | Titers | Day 1 |
|
|
|
|
| Primary | GMCs of Pneumococcal IgG by Cohort and Vaccine Type (VT) Carriage Status - Subgroup Analysis | Approximately 5 mL of blood sample was collected within 24 hours of enrollment. Blood must have been drawn from peripheral veins (eg, arm, foot, or scalp veins). Serum concentrations of anticapsular IgG were determined by ELISA for each of the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in all participants with a collected blood sample. For each cohort, participants were assigned to 2 subgroups: Participant in whom a 13vPnC VT strain had been isolated from the respiratory tract, and participant from whom a 13vPnC VT strain had not been isolated from the respiratory tract (VT carrier versus without VT carrier). | Analysis population for this OM included all participants who signed the informed consent document, met all inclusion/exclusion criteria, and had at least 1 immunogenicity assay value available for analysis. Overall number of participants analyzed indicates the number of participants in this analysis population. Number Analyzed in each row indicates the number of participants with valid and determinate assay results for the specified serotype. | Posted | Geometric Mean | 95% Confidence Interval | microgram per milliliter (µg/mL) | Day 1 |
|
|
|
|
| Primary | GMTs of Pneumococcal MOPA by Cohort and VT Carriage Status - Subgroup Analysis | Approximately 5 mL of blood sample was collected within 24 hours of enrollment. Blood must have been drawn from peripheral veins (eg, arm, foot, or scalp veins). Serum levels of MOPA for each of the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in all 13vPnC cohort participants with adequate blood volume. In the Non-13vPnC cohort, a sample of participants with adequate blood volume was selected, to be equal to the number of the 13vPnC Cohort included for MOPA testing. For each cohort, participants were assigned to 2 subgroups: Participant in whom a 13vPnC VT strain had been isolated from the respiratory tract, and participant from whom a 13vPnC VT strain had not been isolated from the respiratory tract (VT carrier versus without VT carrier). Titer was expressed as reciprocal of the highest serum dilution. | Analysis population for this OM included all participants who signed the informed consent document, met all inclusion/exclusion criteria, and had at least 1 immunogenicity assay value available for analysis. Overall number of participants analyzed indicates the number of participants in this analysis population. Number Analyzed in each row indicates the number of participants with valid and determinate assay results for the specified serotype. | Posted | Number | 95% Confidence Interval | Titers | Day 1 |
|
|
|
|
| 0 |
| 101 |
| 0 |
| 101 |
| 0 |
| 101 |
| EG001 | Non-13vPnC Cohort | The vaccination history of 13vPnC initially was obtained either from the participant's parent/caregiver; confirmation of 13vPnC receipt from vaccine book or image of vaccine book was required. If 13vPnC vaccination was confirmed as not received, and all other inclusion / exclusion criteria were met, this participant was enrolled and assigned to the unvaccinated group (ie, Non-13vPnC Cohort). No vaccines were administered during the study. | 0 | 199 | 0 | 199 | 0 | 199 |
Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
| Serotype: 3 |
|
|
| Serotype: 4 |
|
|
| Serotype: 5 |
|
|
| Serotype: 6A |
|
|
| Serotype: 6B |
|
|
| Serotype: 7F |
|
|
| Serotype: 9V |
|
|
| Serotype: 14 |
|
|
| Serotype: 18C |
|
|
| Serotype: 19A |
|
|
| Serotype: 19F |
|
|
| Serotype: 23F |
|
|
| GMR of 13vPnC Cohort/Non-13vPnC Cohort for Serotype: 3 | GMR | 9.06 | 2-Sided | 95 | 4.72 | 17.39 | GMR=(GMT of 13vPnC Cohort)/(GMT of Non-13vPnC Cohort) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/Non-13vPnC Cohort for Serotype: 4 | GMR | 14.37 | 2-Sided | 95 | 6.25 | 33.05 | GMR=(GMT of 13vPnC Cohort)/(GMT of Non-13vPnC Cohort) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/Non-13vPnC Cohort for Serotype: 5 | GMR | 18.03 | 2-Sided | 95 | 8.84 | 36.80 | GMR=(GMT of 13vPnC Cohort)/(GMT of Non-13vPnC Cohort) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of 13vPnC Cohort/Non-13vPnC Cohort for Serotype: 6A | GMR | 33.88 | 2-Sided | 95 | 14.33 | 80.13 | GMR=(GMT of 13vPnC Cohort)/(GMT of Non-13vPnC Cohort) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/Non-13vPnC Cohort for Serotype: 6B | GMR | 14.05 | 2-Sided | 95 | 6.07 | 32.52 | GMR=(GMT of 13vPnC Cohort)/(GMT of Non-13vPnC Cohort) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/Non-13vPnC Cohort for Serotype: 7F | GMR | 16.99 | 2-Sided | 95 | 7.85 | 36.76 | GMR=(GMT of 13vPnC Cohort)/(GMT of Non-13vPnC Cohort) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/Non-13vPnC Cohort for Serotype: 9V | GMR | 19.31 | 2-Sided | 95 | 9.13 | 40.84 | GMR=(GMT of 13vPnC Cohort)/(GMT of Non-13vPnC Cohort) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/Non-13vPnC Cohort for Serotype: 14 | GMR | 10.46 | 2-Sided | 95 | 4.74 | 23.10 | GMR=(GMT of 13vPnC Cohort)/(GMT of Non-13vPnC Cohort) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/Non-13vPnC Cohort for Serotype: 18C | GMR | 12.13 | 2-Sided | 95 | 6.00 | 24.51 | GMR=(GMT of 13vPnC Cohort)/(GMT of Non-13vPnC Cohort) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/Non-13vPnC Cohort for Serotype: 19A | GMR | 23.65 | 2-Sided | 95 | 10.94 | 51.10 | GMR=(GMT of 13vPnC Cohort)/(GMT of Non-13vPnC Cohort) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/Non-13vPnC Cohort for Serotype: 19F | GMR | 17.62 | 2-Sided | 95 | 8.65 | 35.93 | GMR=(GMT of 13vPnC Cohort)/(GMT of Non-13vPnC Cohort) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/Non-13vPnC Cohort for Serotype: 23F | GMR | 44.46 | 2-Sided | 95 | 19.11 | 103.43 | GMR=(GMT of 13vPnC Cohort)/(GMT of Non-13vPnC Cohort) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
|
| Serotype: 3 |
|
|
| Serotype: 4 |
|
|
| Serotype: 5 |
|
|
| Serotype: 6A |
|
|
| Serotype: 6B |
|
|
| Serotype: 7F |
|
|
| Serotype: 9V |
|
|
| Serotype: 14 |
|
|
| Serotype: 18C |
|
|
| Serotype: 19A |
|
|
| Serotype: 19F |
|
|
| Serotype: 23F |
|
|
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in 13vPnC Cohort for Serotype: 3 | GMR | 0.74 | 2-Sided | 95 | 0.27 | 1.98 | GMR=(GMC of VT+ Subgroup)/(GMC of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in 13vPnC Cohort for Serotype: 4 | GMR | 0.68 | 2-Sided | 95 | 0.21 | 2.19 | GMR=(GMC of VT+ Subgroup)/(GMC of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in 13vPnC Cohort for Serotype: 5 | GMR | 0.82 | 2-Sided | 95 | 0.36 | 1.86 | GMR=(GMC of VT+ Subgroup)/(GMC of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in 13vPnC Cohort for Serotype: 6A | GMR | 0.68 | 2-Sided | 95 | 0.25 | 1.89 | GMR=(GMC of VT+ Subgroup)/(GMC of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in 13vPnC Cohort for Serotype: 6B | GMR | 0.74 | 2-Sided | 95 | 0.27 | 2.07 | GMR=(GMC of VT+ Subgroup)/(GMC of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in 13vPnC Cohort for Serotype: 7F | GMR | 0.42 | 2-Sided | 95 | 0.16 | 1.09 | GMR=(GMC of VT+ Subgroup)/(GMC of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in 13vPnC Cohort for Serotype: 9V | GMR | 0.80 | 2-Sided | 95 | 0.35 | 1.81 | GMR=(GMC of VT+ Subgroup)/(GMC of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in 13vPnC Cohort for Serotype: 14 | GMR | 0.66 | 2-Sided | 95 | 0.20 | 2.24 | GMR=(GMC of VT+ Subgroup)/(GMC of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in 13vPnC Cohort for Serotype: 18C | GMR | 0.60 | 2-Sided | 95 | 0.22 | 1.65 | GMR=(GMC of VT+ Subgroup)/(GMC of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in 13vPnC Cohort for Serotype: 19A | GMR | 1.55 | 2-Sided | 95 | 0.61 | 3.93 | GMR=(GMC of VT+ Subgroup)/(GMC of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in 13vPnC Cohort for Serotype: 19F | GMR | 1.80 | 2-Sided | 95 | 0.65 | 4.99 | GMR=(GMC of VT+ Subgroup)/(GMC of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in 13vPnC Cohort for Serotype: 23F | GMR | 0.47 | 2-Sided | 95 | 0.17 | 1.31 | GMR=(GMC of VT+ Subgroup)/(GMC of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in non-13vPnC Cohort for Serotype: 1 | GMR | 0.65 | 2-Sided | 95 | 0.31 | 1.38 | GMR=(GMC of VT+ Subgroup)/(GMC of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in non-13vPnC Cohort for Serotype: 3 | GMR | 0.70 | 2-Sided | 95 | 0.40 | 1.24 | GMR=(GMC of VT+ Subgroup)/(GMC of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in non-13vPnC Cohort for Serotype: 4 | GMR | 0.73 | 2-Sided | 95 | 0.33 | 1.59 | GMR=(GMC of VT+ Subgroup)/(GMC of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in non-13vPnC Cohort for Serotype: 5 | GMR | 0.80 | 2-Sided | 95 | 0.52 | 1.25 | GMR=(GMC of VT+ Subgroup)/(GMC of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in non-13vPnC Cohort for Serotype: 6A | GMR | 0.93 | 2-Sided | 95 | 0.57 | 1.52 | GMR=(GMC of VT+ Subgroup)/(GMC of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in non-13vPnC Cohort for Serotype: 6B | GMR | 1.53 | 2-Sided | 95 | 0.95 | 2.47 | GMR=(GMC of VT+ Subgroup)/(GMC of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in non-13vPnC Cohort for Serotype: 7F | GMR | 0.74 | 2-Sided | 95 | 0.41 | 1.34 | GMR=(GMC of VT+ Subgroup)/(GMC of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in non-13vPnC Cohort for Serotype: 9V | GMR | 0.73 | 2-Sided | 95 | 0.34 | 1.57 | GMR=(GMC of VT+ Subgroup)/(GMC of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in non-13vPnC Cohort for Serotype: 14 | GMR | 0.44 | 2-Sided | 95 | 0.16 | 1.18 | GMR=(GMC of VT+ Subgroup)/(GMC of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in non-13vPnC Cohort for Serotype: 18C | GMR | 0.59 | 2-Sided | 95 | 0.25 | 1.40 | GMR=(GMC of VT+ Subgroup)/(GMC of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in non-13vPnC Cohort for Serotype: 19A | GMR | 0.79 | 2-Sided | 95 | 0.50 | 1.23 | GMR=(GMC of VT+ Subgroup)/(GMC of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in non-13vPnC Cohort for Serotype: 19F | GMR | 1.14 | 2-Sided | 95 | 0.60 | 2.18 | GMR=(GMC of VT+ Subgroup)/(GMC of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in non-13vPnC Cohort for Serotype: 23F | GMR | 1.08 | 2-Sided | 95 | 0.68 | 1.72 | GMR=(GMC of VT+ Subgroup)/(GMC of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT+ Subgroups for Serotype: 1 | GMR | 10.30 | 2-Sided | 95 | 2.44 | 43.49 | GMR=(GMC of 13vPnC VT+ Subgroup)/(GMC of non-13vPnC VT+ Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT+ Subgroups for Serotype: 3 | GMR | 6.17 | 2-Sided | 95 | 2.07 | 18.42 | GMR=(GMC of 13vPnC VT+ Subgroup)/(GMC of non-13vPnC VT+ Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT+ Subgroups for Serotype: 4 | GMR | 18.70 | 2-Sided | 95 | 4.35 | 80.37 | GMR=(GMC of 13vPnC VT+ Subgroup)/(GMC of non-13vPnC VT+ Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT+ Subgroups for Serotype: 5 | GMR | 2.50 | 2-Sided | 95 | 1.14 | 5.52 | GMR=(GMC of 13vPnC VT+ Subgroup)/(GMC of non-13vPnC VT+ Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT+ Subgroups for Serotype: 6A | GMR | 5.24 | 2-Sided | 95 | 2.33 | 11.80 | GMR=(GMC of 13vPnC VT+ Subgroup)/(GMC of non-13vPnC VT+ Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT+ Subgroups for Serotype: 6B | GMR | 3.77 | 2-Sided | 95 | 1.47 | 9.65 | GMR=(GMC of 13vPnC VT+ Subgroup)/(GMC of non-13vPnC VT+ Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT+ Subgroups for Serotype: 7F | GMR | 5.94 | 2-Sided | 95 | 1.65 | 21.36 | GMR=(GMC of 13vPnC VT+ Subgroup)/(GMC of non-13vPnC VT+ Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT+ Subgroups for Serotype: 9V | GMR | 4.44 | 2-Sided | 95 | 1.17 | 16.87 | GMR=(GMC of 13vPnC VT+ Subgroup)/(GMC of non-13vPnC VT+ Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT+ Subgroups for Serotype: 14 | GMR | 90.80 | 2-Sided | 95 | 16.67 | 494.56 | GMR=(GMC of 13vPnC VT+ Subgroup)/(GMC of non-13vPnC VT+ Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT+ Subgroups for Serotype: 18C | GMR | 17.83 | 2-Sided | 95 | 3.79 | 83.78 | GMR=(GMC of 13vPnC VT+ Subgroup)/(GMC of non-13vPnC VT+ Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT+ Subgroups for Serotype: 19A | GMR | 8.11 | 2-Sided | 95 | 3.60 | 18.30 | GMR=(GMC of 13vPnC VT+ Subgroup)/(GMC of non-13vPnC VT+ Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT+ Subgroups for Serotype: 19F | GMR | 15.29 | 2-Sided | 95 | 4.64 | 50.35 | GMR=(GMC of 13vPnC VT+ Subgroup)/(GMC of non-13vPnC VT+ Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT+ Subgroups for Serotype: 23F | GMR | 4.19 | 2-Sided | 95 | 1.72 | 10.25 | GMR=(GMC of 13vPnC VT+ Subgroup)/(GMC of non-13vPnC VT+ Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT- or Sp- Subgroups for Serotype: 1 | GMR | 13.93 | 2-Sided | 95 | 9.14 | 21.23 | GMR=(GMC of 13vPnC VT- or Sp- Subgroup)/(GMC of non-13vPnC VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT- or Sp- Subgroups for Serotype: 3 | GMR | 5.86 | 2-Sided | 95 | 4.17 | 8.24 | GMR=(GMC of 13vPnC VT- or Sp- Subgroup)/(GMC of non-13vPnC VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT- or Sp- Subgroups for Serotype: 4 | GMR | 19.97 | 2-Sided | 95 | 12.80 | 31.15 | GMR=(GMC of 13vPnC VT- or Sp- Subgroup)/(GMC of non-13vPnC VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT- or Sp- Subgroups for Serotype: 5 | GMR | 2.46 | 2-Sided | 95 | 1.87 | 3.24 | GMR=(GMC of 13vPnC VT- or Sp- Subgroup)/(GMC of non-13vPnC VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT- or Sp- Subgroups for Serotype: 6A | GMR | 7.12 | 2-Sided | 95 | 5.05 | 10.03 | GMR=(GMC of 13vPnC VT- or Sp- Subgroup)/(GMC of non-13vPnC VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT- or Sp- Subgroups for Serotype: 6B | GMR | 7.78 | 2-Sided | 95 | 5.54 | 10.92 | GMR=(GMC of 13vPnC VT- or Sp- Subgroup)/(GMC of non-13vPnC VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT- or Sp- Subgroups for Serotype: 7F | GMR | 10.40 | 2-Sided | 95 | 7.40 | 14.61 | GMR=(GMC of 13vPnC VT- or Sp- Subgroup)/(GMC of non-13vPnC VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT- or Sp- Subgroups for Serotype: 9V | GMR | 4.07 | 2-Sided | 95 | 3.04 | 5.47 | GMR=(GMC of 13vPnC VT- or Sp- Subgroup)/(GMC of non-13vPnC VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT- or Sp- Subgroups for Serotype: 14 | GMR | 60.32 | 2-Sided | 95 | 37.25 | 97.67 | GMR=(GMC of 13vPnC VT- or Sp- Subgroup)/(GMC of non-13vPnC VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT- or Sp- Subgroups for Serotype: 18C | GMR | 17.35 | 2-Sided | 95 | 11.37 | 26.47 | GMR=(GMC of 13vPnC VT- or Sp- Subgroup)/(GMC of non-13vPnC VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT- or Sp- Subgroups for Serotype: 19A | GMR | 4.11 | 2-Sided | 95 | 3.00 | 5.62 | GMR=(GMC of 13vPnC VT- or Sp- Subgroup)/(GMC of non-13vPnC VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT- or Sp- Subgroups for Serotype: 19F | GMR | 9.68 | 2-Sided | 95 | 6.65 | 14.08 | GMR=(GMC of 13vPnC VT- or Sp- Subgroup)/(GMC of non-13vPnC VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT- or Sp- Subgroups for Serotype: 23F | GMR | 9.70 | 2-Sided | 95 | 6.90 | 13.64 | GMR=(GMC of 13vPnC VT- or Sp- Subgroup)/(GMC of non-13vPnC VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMC of 13vPnC Cohort to the GMC of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (IgG) using Student's t distribution. |
|
| Serotype: 3 |
|
|
| Serotype: 4 |
|
|
| Serotype: 5 |
|
|
| Serotype: 6A |
|
|
| Serotype: 6B |
|
|
| Serotype: 7F |
|
|
| Serotype: 9V |
|
|
| Serotype: 14 |
|
|
| Serotype: 18C |
|
|
| Serotype: 19A |
|
|
| Serotype: 19F |
|
|
| Serotype: 23F |
|
|
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in 13vPnC Cohort for Serotype: 3 | GMR | 0.54 | 2-Sided | 95 | 0.10 | 2.92 | GMR=(GMT of VT+ Subgroup)/(GMT of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in 13vPnC Cohort for Serotype: 4 | GMR | 0.45 | 2-Sided | 95 | 0.10 | 2.07 | GMR=(GMT of VT+ Subgroup)/(GMT of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in 13vPnC Cohort for Serotype: 5 | GMR | 1.78 | 2-Sided | 95 | 0.27 | 11.75 | GMR=(GMT of VT+ Subgroup)/(GMT of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in 13vPnC Cohort for Serotype: 6A | GMR | 0.23 | 2-Sided | 95 | 0.03 | 1.65 | GMR=(GMT of VT+ Subgroup)/(GMT of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in 13vPnC Cohort for Serotype: 6B | GMR | 0.06 | 2-Sided | 95 | 0.01 | 0.44 | GMR=(GMT of VT+ Subgroup)/(GMT of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in 13vPnC Cohort for Serotype: 7F | GMR | 1.21 | 2-Sided | 95 | 0.56 | 2.65 | GMR=(GMT of VT+ Subgroup)/(GMT of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in 13vPnC Cohort for Serotype: 9V | GMR | 0.20 | 2-Sided | 95 | 0.03 | 1.26 | GMR=(GMT of VT+ Subgroup)/(GMT of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in 13vPnC Cohort for Serotype: 14 | GMR | 0.36 | 2-Sided | 95 | 0.08 | 1.55 | GMR=(GMT of VT+ Subgroup)/(GMT of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in 13vPnC Cohort for Serotype: 18C | GMR | 0.82 | 2-Sided | 95 | 0.15 | 4.47 | GMR=(GMT of VT+ Subgroup)/(GMT of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in 13vPnC Cohort for Serotype: 19A | GMR | 1.35 | 2-Sided | 95 | 0.19 | 9.44 | GMR=(GMT of VT+ Subgroup)/(GMT of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in 13vPnC Cohort for Serotype: 19F | GMR | 3.87 | 2-Sided | 95 | 0.67 | 22.42 | GMR=(GMT of VT+ Subgroup)/(GMT of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in 13vPnC Cohort for Serotype: 23F | GMR | 0.27 | 2-Sided | 95 | 0.05 | 1.52 | GMR=(GMT of VT+ Subgroup)/(GMT of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in non-13vPnC Cohort for Serotype: 1 | GMR | 0.76 | 2-Sided | 95 | 0.19 | 3.07 | GMR=(GMT of VT+ Subgroup)/(GMT of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in non-13vPnC Cohort for Serotype: 3 | GMR | 1.02 | 2-Sided | 95 | 0.42 | 2.46 | GMR=(GMT of VT+ Subgroup)/(GMT of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in non-13vPnC Cohort for Serotype: 4 | GMR | 0.44 | 2-Sided | 95 | 0.05 | 3.73 | GMR=(GMT of VT+ Subgroup)/(GMT of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in non-13vPnC Cohort for Serotype: 5 | GMR | 0.63 | 2-Sided | 95 | 0.15 | 2.73 | GMR=(GMT of VT+ Subgroup)/(GMT of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in non-13vPnC Cohort for Serotype: 6A | GMR | 0.88 | 2-Sided | 95 | 0.11 | 6.99 | GMR=(GMT of VT+ Subgroup)/(GMT of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in non-13vPnC Cohort for Serotype: 6B | GMR | 1.90 | 2-Sided | 95 | 0.29 | 12.51 | GMR=(GMT of VT+ Subgroup)/(GMT of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in non-13vPnC Cohort for Serotype: 7F | GMR | 2.45 | 2-Sided | 95 | 0.34 | 17.43 | GMR=(GMT of VT+ Subgroup)/(GMT of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in non-13vPnC Cohort for Serotype: 9V | GMR | 1.43 | 2-Sided | 95 | 0.27 | 7.70 | GMR=(GMT of VT+ Subgroup)/(GMT of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in non-13vPnC Cohort for Serotype: 14 | GMR | 2.30 | 2-Sided | 95 | 0.30 | 17.41 | GMR=(GMT of VT+ Subgroup)/(GMT of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in non-13vPnC Cohort for Serotype: 18C | GMR | 0.65 | 2-Sided | 95 | 0.14 | 2.97 | GMR=(GMT of VT+ Subgroup)/(GMT of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in non-13vPnC Cohort for Serotype: 19A | GMR | 1.51 | 2-Sided | 95 | 0.28 | 8.21 | GMR=(GMT of VT+ Subgroup)/(GMT of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in non-13vPnC Cohort for Serotype: 19F | GMR | 0.63 | 2-Sided | 95 | 0.13 | 2.97 | GMR=(GMT of VT+ Subgroup)/(GMT of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of VT+ Subgroup/VT- or Sp- Subgroup in non-13vPnC Cohort for Serotype: 23F | GMR | 1.23 | 2-Sided | 95 | 0.15 | 10.24 | GMR=(GMT of VT+ Subgroup)/(GMT of VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT+ Subgroups for Serotype: 1 | GMR | 3.15 | 2-Sided | 95 | 0.41 | 23.91 | GMR=(GMT of 13vPnC VT+ Subgroup)/(GMT of non-13vPnC VT+ Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT+ Subgroups for Serotype: 3 | GMR | 5.02 | 2-Sided | 95 | 1.45 | 17.39 | GMR=(GMT of 13vPnC VT+ Subgroup)/(GMT of non-13vPnC VT+ Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT+ Subgroups for Serotype: 4 | GMR | 13.70 | 2-Sided | 95 | 1.32 | 141.81 | GMR=(GMT of 13vPnC VT+ Subgroup)/(GMT of non-13vPnC VT+ Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT+ Subgroups for Serotype: 5 | GMR | 48.41 | 2-Sided | 95 | 6.16 | 380.54 | GMR=(GMT of 13vPnC VT+ Subgroup)/(GMT of non-13vPnC VT+ Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT+ Subgroups for Serotype: 6A | GMR | 10.47 | 2-Sided | 95 | 0.48 | 229.10 | GMR=(GMT of 13vPnC VT+ Subgroup)/(GMT of non-13vPnC VT+ Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT+ Subgroups for Serotype: 6B | GMR | 0.68 | 2-Sided | 95 | 0.02 | 19.83 | GMR=(GMT of 13vPnC VT+ Subgroup)/(GMT of non-13vPnC VT+ Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT+ Subgroups for Serotype: 7F | GMR | 10.53 | 2-Sided | 95 | 1.98 | 55.96 | GMR=(GMT of 13vPnC VT+ Subgroup)/(GMT of non-13vPnC VT+ Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT+ Subgroups for Serotype: 9V | GMR | 3.32 | 2-Sided | 95 | 0.19 | 56.82 | GMR=(GMT of 13vPnC VT+ Subgroup)/(GMT of non-13vPnC VT+ Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT+ Subgroups for Serotype: 14 | GMR | 2.00 | 2-Sided | 95 | 0.06 | 63.12 | GMR=(GMT of 13vPnC VT+ Subgroup)/(GMT of non-13vPnC VT+ Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT+ Subgroups for Serotype: 18C | GMR | 16.31 | 2-Sided | 95 | 2.15 | 123.48 | GMR=(GMT of 13vPnC VT+ Subgroup)/(GMT of non-13vPnC VT+ Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT+ Subgroups for Serotype: 19A | GMR | 24.16 | 2-Sided | 95 | 1.59 | 367.81 | GMR=(GMT of 13vPnC VT+ Subgroup)/(GMT of non-13vPnC VT+ Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT+ Subgroups for Serotype: 19F | GMR | 95.06 | 2-Sided | 95 | 13.08 | 691.01 | GMR=(GMT of 13vPnC VT+ Subgroup)/(GMT of non-13vPnC VT+ Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT+ Subgroups for Serotype: 23F | GMR | 10.49 | 2-Sided | 95 | 0.64 | 171.84 | GMR=(GMT of 13vPnC VT+ Subgroup)/(GMT of non-13vPnC VT+ Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT- or Sp- Subgroups for Serotype: 1 | GMR | 4.86 | 2-Sided | 95 | 2.15 | 10.96 | GMR=(GMT of 13vPnC VT- or Sp- Subgroup)/(GMT of non-13vPnC VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT- or Sp- Subgroups for Serotype: 3 | GMR | 9.57 | 2-Sided | 95 | 4.50 | 20.36 | GMR=(GMT of 13vPnC VT- or Sp- Subgroup)/(GMT of non-13vPnC VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT- or Sp- Subgroups for Serotype: 4 | GMR | 13.40 | 2-Sided | 95 | 5.20 | 34.51 | GMR=(GMT of 13vPnC VT- or Sp- Subgroup)/(GMT of non-13vPnC VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT- or Sp- Subgroups for Serotype: 5 | GMR | 17.15 | 2-Sided | 95 | 7.76 | 37.91 | GMR=(GMT of 13vPnC VT- or Sp- Subgroup)/(GMT of non-13vPnC VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT- or Sp- Subgroups for Serotype: 6A | GMR | 40.20 | 2-Sided | 95 | 15.16 | 106.65 | GMR=(GMT of 13vPnC VT- or Sp- Subgroup)/(GMT of non-13vPnC VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT- or Sp- Subgroups for Serotype: 6B | GMR | 20.38 | 2-Sided | 95 | 8.39 | 49.51 | GMR=(GMT of 13vPnC VT- or Sp- Subgroup)/(GMT of non-13vPnC VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT- or Sp- Subgroups for Serotype: 7F | GMR | 21.22 | 2-Sided | 95 | 8.65 | 52.07 | GMR=(GMT of 13vPnC VT- or Sp- Subgroup)/(GMT of non-13vPnC VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT- or Sp- Subgroups for Serotype: 9V | GMR | 23.73 | 2-Sided | 95 | 10.39 | 54.19 | GMR=(GMT of 13vPnC VT- or Sp- Subgroup)/(GMT of non-13vPnC VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT- or Sp- Subgroups for Serotype: 14 | GMR | 12.84 | 2-Sided | 95 | 5.46 | 30.22 | GMR=(GMT of 13vPnC VT- or Sp- Subgroup)/(GMT of non-13vPnC VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT- or Sp- Subgroups for Serotype: 18C | GMR | 12.88 | 2-Sided | 95 | 5.95 | 27.88 | GMR=(GMT of 13vPnC VT- or Sp- Subgroup)/(GMT of non-13vPnC VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT- or Sp- Subgroups for Serotype: 19A | GMR | 26.99 | 2-Sided | 95 | 11.46 | 63.58 | GMR=(GMT of 13vPnC VT- or Sp- Subgroup)/(GMT of non-13vPnC VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT- or Sp- Subgroups for Serotype: 19F | GMR | 15.53 | 2-Sided | 95 | 7.02 | 34.38 | GMR=(GMT of 13vPnC VT- or Sp- Subgroup)/(GMT of non-13vPnC VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |
| GMR of 13vPnC Cohort/non-13vPnC Cohort in VT- or Sp- Subgroups for Serotype: 23F | GMR | 48.73 | 2-Sided | 95 | 18.67 | 127.16 | GMR=(GMT of 13vPnC VT- or Sp- Subgroup)/(GMT of non-13vPnC VT- or Sp- Subgroup) | Superiority | The 2-sided 95% CI on the GMRs (the GMT of 13vPnC Cohort to the GMT of Non-13vPnC Cohort) for all 13 serotypes are provided and those 95% CIs were constructed by back transformation of the CIs for the mean difference of the measures on the logarithmically transformed scale (MOPA) using Student's t distribution. |